in vivo（生体内）CROの市場規模、シェア、動向分析レポート：モデルタイプ別、モダリティ別、適応症別、GLPタイプ別、地域別、セグメント別予測、2024年～2030年

in vivo（生体内）CRO市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のin vivo CRO市場規模は2030年までに79億3,000万米ドルに達し、予測期間中のCAGRは8.1％を記録すると予測されています。

新興国における医薬品市場の成長、数多くのin vivo細胞治療に対する旺盛な需要、材料科学の急速な進歩、薬剤とデバイスの組み合わせの複雑さなどが、この地域におけるサービスの需要につながっています。加えて、in vivo前臨床および臨床研究の増加、規制当局の承認、市場参入企業によるサービスの拡大、さまざまな疾患の負担が市場収益に寄与しています。また、新興経済諸国における前臨床および臨床サービスの低コストでのアウトソーシングの増加は、in vivo CRO市場の成長を支える主要な要因の一つです。

同様に、新興経済国への医薬品のオフショアリングが増加していることも、同市場に莫大な需要を生み出しています。先進諸国における予算の精査、価格圧力、償還制度の変更は、インドや中国などの新興諸国における医薬品スポンサーによるコスト抑制策の採用を増加させると予想される主な要因の一部です。新興諸国では、前臨床in vivoサービスなどの開発サービスを契約サービスプロバイダーにアウトソーシングすることで、品質保証・薬事サービスの需要が高まり、in vivoアウトソーシングサービスの需要増加に寄与すると予想されます。FDA承認のための厳格なプロセスやEU地域の規制変更は、欧州での承認プロセスを複雑にしていると予想されます。これらは、製薬会社の新興国へのオフショアリングに寄与する主な要因のひとつです。

COVID-19パンデミックは当初、臨床試験業界に悪影響を与えたが、in vivo CRO市場も同様でした。COVID-19に対応してバイオ医薬品業界がワクチンと治療法の開発に重点を移した結果、他の疾患の臨床試験を混乱させる可能性という予期せぬ結果を招いた。細胞・遺伝子治療業界で事業を展開する企業が直面する重要な問題のひとつは、必要とされる臨床試験実施施設において、患者に治療薬を適時に提供できないことです。さらに、細胞ベースの治療薬の投与は、パンデミック後にいくつかの課題を突きつけています。病院は、SARS-CoV-2の感染、特に弱い立場の人への感染を懸念し、細胞治療サービスの提供を躊躇しています。患者は、封鎖や渡航禁止のために細胞治療センターを訪れることができないです。

さらに、主要参入企業は、世界の足跡とサービス／製品ポートフォリオを拡大するために、M&A、パートナーシップ、協定、提携、サービス開始などの戦略に取り組んでいます。例えば、2023年4月、PsychoGenics, Inc.は、表現型創薬を強化するための薬理脳波プラットフォームであるeCubeの発売を発表しました。同様に、バイオサイトーゲンは2023年2月、特定の標的をターゲットとする100種類以上の完全ヒト型ナノボディ医薬品を開発する「ナノ100プロジェクト」を発表しました。この試みは、完全ヒト型ナノボディを産生できるマウスモデルであるバイオサイトーゲン社独自のRenNanoと、先進的なin vitroおよびin vivo抗体スクリーニング・プラットフォームを組み合わせたものです。これらの統合技術を活用することで、バイオシトゲンは完全ヒト型ナノボディ医薬品の広範な開発を促進する態勢を整えています。

in vivo CRO市場レポートハイライト

• げっ歯類は遺伝的にヒトに似ているため、一定のモデル需要があり、げっ歯類ベースのセグメントは81.8%の最大売上シェアを占めました。また、サイズが小さく、ライフサイクルが短く、メンテナンスが容易で、遺伝資源が入手しやすいことから、in vivo CRO研究において最も普及している動物種となっています。
• 低分子セグメントはin vivo CRO市場を独占しています。この成長は、医薬品候補の開発における低分子の需要に起因しています。加えて、低分子は少量で高い治療効果を発揮することが、このセグメントの成長を後押ししています。
• 2023年の市場規模はがん分野が圧倒的に大きく、成長の主な要因としては、がん負担の増大、新規遺伝子治療に対する需要の急増、がん免疫療法の前臨床試験などが挙げられます。米国遺伝子細胞治療学会によると、CAR T細胞療法の約97％はがんを適応症として開発されています。
• 中枢神経系疾患分野は、脳疾患をターゲットとした様々なモデルベースの治験薬の有効性により、最も速い成長が見込まれています。
• GLP毒性学セグメントは、特定のガイドラインに従って実施される標準化試験の増加により、2023年に最大の市場シェアを占めました。
• 北米は、2023年のin vivo CRO市場において50.0%の最大収益シェアを占めました。同地域の成長は、定評のある市場プレイヤーの存在、さまざまな疾患による負担の増加、同地域におけるCROの需要拡大に起因しています。その他の成長要因は、研究開発活動、前臨床試験、市場プレイヤーのイノベーションの増加です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 in vivo CRO市場：変数、動向および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• in vivo CRO市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • 価格分析

第4章 in vivo CRO市場：モデルタイプの推定・動向分析

• モデルタイプの市場シェア、2023年と2030年
• セグメントダッシュボード
• モデルタイプ別の世界のin vivo CRO市場の見通し
• 市場規模、予測および動向分析、2018年から2030年まで

第5章 in vivo CRO市場：モダリティの推定・動向分析

• モダリティの市場シェア、2023年と2030年
• セグメントダッシュボード
• モダリティ別の世界のin vivo CRO市場の見通し
• 市場規模、予測および動向分析、2018年から2030年まで

第6章 in vivo CRO市場：適応症の推定・動向分析

• 適応症の市場シェア、2023年と2030年
• セグメントダッシュボード
• 適応症別の世界のin vivo CRO市場の見通し
• 市場規模、予測および動向分析、2018年から2030年まで

第7章 in vivo CRO市場：GLPタイプの推定・動向分析

• GLPタイプの市場シェア、2023年と2030年
• セグメントダッシュボード
• GLPタイプ別の世界のin vivo CRO市場の見通し
• 市場規模、予測および動向分析、2018年から2030年まで

第8章 in vivo CRO市場：地域の推定・動向分析

• 地域の市場シェア分析、2023年と2030年
• 地域の市場ダッシュボード
• 世界の地域の市場スナップショット
• 市場規模と予測動向分析、2018年から2030年まで
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 会社/競合の分類
• ベンダー情勢
  • IQVIA Inc.
  • Crown Bioscience
  • Taconic Biosciences, Inc.
  • PsychoGenics Inc.
  • Evotec
  • Janvier Labs
  • Biocytogen Boston Corp
  • GemPharmatech
  • Charles River Laboratories
  • Icon Plc
  • Labcorp Drug Development
  • Parexel International Corporation
  • SMO Clinical Research（I）Pvt Ltd.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America in vivo CRO market, by region, 2018 - 2030 (USD Million)
• Table 3 North America in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 4 North America in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 5 North America in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 6 North America in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 7 U.S. in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 8 U.S. in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 9 U.S. in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 10 U.S. in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 11 Canada in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 12 Canada in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 13 Canada in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 14 Canada in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 15 Europe in vivo CRO market, by region, 2018 - 2030 (USD Million)
• Table 16 Europe in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 17 Europe in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 18 Europe in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 19 Europe in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 20 Germany in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 21 Germany in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 22 Germany in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 23 Germany in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 24 UK in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 25 UK in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 26 UK in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 27 UK in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 28 France in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 29 France in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 30 France in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 31 France in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 32 Italy in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 33 Italy in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 34 Italy in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 35 Italy in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 36 Spain in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 37 Spain in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 38 Spain in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 39 Spain in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 40 Denmark in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 41 Denmark in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 42 Denmark in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 43 Denmark in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 44 Sweden in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 45 Sweden in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 46 Sweden in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 47 Sweden in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 48 Norway in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 49 Norway in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 50 Norway in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 51 Norway in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 52 Asia Pacific in vivo CRO market, by region, 2018 - 2030 (USD Million)
• Table 53 Asia Pacific in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 54 Asia Pacific in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 55 Asia Pacific in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 57 China in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 58 China in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 59 China in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 60 China in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 61 Japan in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 62 Japan in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 63 Japan in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 64 Japan in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 65 India in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 66 India in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 67 India in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 68 India in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 69 South Korea in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 70 South Korea in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 71 South Korea in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 72 South Korea in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 73 Australia in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 74 Australia in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 75 Australia in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 76 Australia in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 77 Thailand in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 78 Thailand in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 79 Thailand in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 80 Thailand in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 81 Latin America in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 82 Latin America in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 83 Latin America in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 84 Latin America in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 85 Brazil in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 86 Brazil in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 87 Brazil in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 88 Brazil in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 89 Mexico in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 90 Mexico in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 91 Mexico in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 92 Mexico in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 93 Argentina in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 94 Argentina in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 95 Argentina in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 96 Argentina in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 97 MEA in vivo CRO market, by region, 2018 - 2030 (USD Million)
• Table 98 MEA in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 99 MEA in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 100 MEA in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 101 MEA in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 102 South Africa in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 103 South Africa in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 104 South Africa in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 105 South Africa in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 106 Saudi Arabia in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 107 Saudi Arabia in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 110 UAE in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 111 UAE in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 112 UAE in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 113 UAE in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
• Table 114 Kuwait in vivo CRO market, by model type, 2018 - 2030 (USD Million)
• Table 115 Kuwait in vivo CRO market, by modality, 2018 - 2030 (USD Million)
• Table 116 Kuwait in vivo CRO market, by indication, 2018 - 2030 (USD Million)
• Table 117 Kuwait in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 In vivo CRO market: market outlook
• Fig. 14 In vivo CRO competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 In vivo CRO market driver impact
• Fig. 20 In vivo CRO market restraint impact
• Fig. 21 In vivo CRO market strategic initiatives analysis
• Fig. 22 In vivo CRO market: Model type movement analysis
• Fig. 23 In vivo CRO market: Model type outlook and key takeaways
• Fig. 24 Rodent based market estimates and forecast, 2018 - 2030
• Fig. 25 Rat models estimates and forecast, 2018 - 2030
• Fig. 26 Mice Models market estimates and forecast, 2018 - 2030
• Fig. 27 Others estimates and forecast, 2018 - 2030
• Fig. 28 Non-rodent based market estimates and forecast, 2018 - 2030
• Fig. 29 In vivo CRO Market: Modality movement Analysis
• Fig. 30 In vivo CRO market: Modality outlook and key takeaways
• Fig. 31 Small molecules market estimates and forecasts, 2018 - 2030
• Fig. 32 Large molecules market estimates and forecasts,2018 - 2030
• Fig. 33 Cell & gene therapy market estimates and forecasts,2018 - 2030
• Fig. 34 CAR T-cell therapies market estimates and forecasts, 2018 - 2030
• Fig. 35 CAR-NK cell therapy market estimates and forecasts, 2018 - 2030
• Fig. 36 TCR-T cell therapy market estimates and forecasts, 2018 - 2030
• Fig. 37 Other (Includes- TCR-NK, CARM, and TAC-T) market estimates and forecasts, 2018 - 2030
• Fig. 38 RNA therapy market estimates and forecasts, 2018 - 2030
• Fig. 39 Others market estimates and forecasts, 2018 - 2030
• Fig. 40 In vivo CRO market: Indication movement analysis
• Fig. 41 In vivo CRO market: Indication outlook and key takeaways
• Fig. 42 Oncology market estimates and forecasts, 2018 - 2030
• Fig. 43 Blood cancer market estimates and forecasts,2018 - 2030
• Fig. 44 Solid tumor market estimates and forecasts, 2018 - 2030
• Fig. 45 Syngeneic model market estimates and forecasts,2018 - 2030
• Fig. 46 Syngeneic model market estimates and forecasts, 2018 - 2030
• Fig. 47 Xenograft market estimates and forecasts,2018 - 2030
• Fig. 48 Others market estimates and forecasts,2018 - 2030
• Fig. 49 CNS conditions market estimates and forecasts,2018 - 2030
• Fig. 50 Epilepsy market estimates and forecasts,2018 - 2030
• Fig. 51 Parkinson's disease market estimates and forecasts,2018 - 2030
• Fig. 52 Huntington's disease market estimates and forecasts,2018 - 2030
• Fig. 53 Stroke market estimates and forecasts,2018 - 2030
• Fig. 54 Muscular dystrophy market estimates and forecasts,2018 - 2030
• Fig. 55 Alzheimer's disease market estimates and forecasts,2018 - 2030
• Fig. 56 Traumatic brain injury market estimates and forecasts,2018 - 2030
• Fig. 57 Amyotrophic lateral sclerosis (ALS) market estimates and forecasts,2018 - 2030
• Fig. 58 Spinal muscular atrophy market estimates and forecasts,2018 - 2030
• Fig. 59 Muscle regeneration market estimates and forecasts,2018 - 2030
• Fig. 60 Other neurodevelopment disorders market estimates and forecasts,2018 - 2030
• Fig. 61 Diabetes market estimates and forecasts,2018 - 2030
• Fig. 62 Obesity market estimates and forecasts,2018 - 2030
• Fig. 63 Pain management market estimates and forecasts,2018 - 2030
• Fig. 64 Chronic pain market estimates and forecasts,2018 - 2030
• Fig. 65 Acute pain market estimates and forecasts,2018 - 2030
• Fig. 66 Autoimmune/inflammation conditions market estimates and forecasts,2018 - 2030
• Fig. 67 Rheumatoid arthritis market estimates and forecasts,2018 - 2030
• Fig. 68 Multiple sclerosis market estimates and forecasts,2018 - 2030
• Fig. 69 Osteoarthritis market estimates and forecasts,2018 - 2030
• Fig. 70 Irritable bowel syndrome market estimates and forecasts,2018 - 2030
• Fig. 71 Others market estimates and forecasts,2018 - 2030
• Fig. 72 Others market estimates and forecasts,2018 - 2030
• Fig. 73 Global in vivo CRO market: Regional movement analysis
• Fig. 74 Global in vivo CRO market: Regional outlook and key takeaways
• Fig. 75 Global in vivo CRO market share and leading players
• Fig. 76 North America market share and leading players
• Fig. 77 Europe market share and leading players
• Fig. 78 Asia Pacific market share and leading players
• Fig. 79 Latin America market share and leading players
• Fig. 80 Middle East & Africa market share and leading players
• Fig. 81 North America, by country
• Fig. 82 North America
• Fig. 83 North America market estimates and forecasts, 2018 - 2030
• Fig. 84 U.S.
• Fig. 85 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 86 Canada
• Fig. 87 Canada market estimates and forecasts, 2018 - 2030
• Fig. 88 Europe
• Fig. 89 Europe market estimates and forecasts, 2018 - 2030
• Fig. 90 UK
• Fig. 91 UK market estimates and forecasts, 2018 - 2030
• Fig. 92 Germany
• Fig. 93 Germany market estimates and forecasts, 2018 - 2030
• Fig. 94 France
• Fig. 95 France market estimates and forecasts, 2018 - 2030
• Fig. 96 Italy
• Fig. 97 Italy market estimates and forecasts, 2018 - 2030
• Fig. 98 Spain
• Fig. 99 Spain market estimates and forecasts, 2018 - 2030
• Fig. 100 Denmark
• Fig. 101 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 102 Sweden
• Fig. 103 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 104 Norway
• Fig. 105 Norway market estimates and forecasts, 2018 - 2030
• Fig. 106 Asia Pacific
• Fig. 107 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 108 China
• Fig. 109 China market estimates and forecasts, 2018 - 2030
• Fig. 110 Japan
• Fig. 111 Japan market estimates and forecasts, 2018 - 2030
• Fig. 112 India
• Fig. 113 India market estimates and forecasts, 2018 - 2030
• Fig. 114 Thailand
• Fig. 115 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 116 South Korea
• Fig. 117 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 118 Australia
• Fig. 119 Australia market estimates and forecasts, 2018 - 2030
• Fig. 120 Latin America
• Fig. 121 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 122 Brazil
• Fig. 123 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 124 Mexico
• Fig. 125 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 126 Argentina
• Fig. 127 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 128 Middle East and Africa
• Fig. 129 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 130 South Africa
• Fig. 131 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 132 Saudi Arabia
• Fig. 133 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 134 UAE
• Fig. 135 UAE market estimates and forecasts, 2018 - 2030
• Fig. 136 Kuwait
• Fig. 137 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 138 Market share of key market players- In vivo CRO market

In Vivo CRO Market Growth & Trends:

The global in vivo CRO market size is expected to reach USD 7.93 billion by 2030, registering a CAGR of 8.1% during the forecast period, according to a new report by Grand View Research, Inc. The growth of the pharmaceutical market in emerging countries, along with strong demand for numerous in vivo cell therapies, rapid advancements in material sciences, and complexities of drug-device combinations, has led to the demand for services in the region. Additionally, rising in vivo preclinical and clinical research, regulatory approval, expanding services by market players, and the burden of different diseases contribute to market earnings. Also, increasing outsourcing of preclinical and clinical services across developing economies at a lower cost is one of the major factors supporting the growth of in vivo CRO market.

Likewise, the increase in offshoring drugs to emerging economies has created immense demand for the market. Budget scrutiny in developed countries, pricing pressure, and changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost-containment measures by drug sponsors in emerging countries such as India and China. Outsourcing development services such as preclinical in vivo services to contract service providers in emerging countries is expected to boost the demand for quality assurance & regulatory affairs services, thereby contributing to the rising demand for in vivo outsourced services. Stringent processes for FDA approval and regulatory changes in the EU region are expected to make the approval process in Europe complex. They are some of the major factors contributing to the offshoring of drug companies to emerging countries.

The COVID-19 pandemic has initially negatively impacted the clinical trials industry and the in vivo CRO market was no different! The shift in the focus of the biopharmaceutical industry on developing vaccines & therapies in response to COVID-19 has resulted in the unintended consequences of potentially disrupting clinical trials for other diseases. One of the key issues faced by companies operating in the cell and gene therapy industry is the untimely delivery of therapies to patients at required clinical sites. In addition, the administration of cell-based therapeutics poses several post-pandemic challenges. Hospitals have shown hesitation in offering cell therapy services owing to concerns over transmission of SARS-CoV-2, especially to vulnerable individuals. Patients have not been able to visit cell therapy centers either owing to the lockdowns or travel bans.

Furthermore, the key participants are engaged in strategies such as mergers & acquisitions, partnerships, agreements, collaborations, and service launches, among others, to expand their global footprints and service/product portfolio. For instance, in April 2023, PsychoGenics, Inc. announced the launch of eCube, a pharmaco-electroencephalography platform, to enhance phenotypic drug discovery. Similarly, in February 2023, Biocytogen recently introduced "the Nano 100 Project" to develop over 100 fully human nanobody drugs that target specific targets. This endeavor involves combining Biocytogen's proprietary RenNano, a mouse model capable of producing fully human nanobodies, with their advanced in vitro and in vivo antibody screening platforms. By leveraging these integrated technologies, Biocytogen is poised to facilitate the extensive development of fully human nanobody drugs.

In Vivo CRO Market Report Highlights:

• The rodent-based segment held the largest revenue share of 81.8% owing to constant model demand as they are genetically similar to humans. Besides, their small size, short life cycle, ease of maintenance, and availability of genetic resources, make them the most prevalent species in in-vivo CRO research
• The small molecule segment dominated the in vivo CRO market. The growth is attributed to the demand for small molecules in the development of drug candidates. In addition, the strong therapeutic effect of small molecules in a small dose is the key factor aiding segment growth
• The oncology segment dominated the market in 2023, the key factors contributing to the growth include the growing burden of cancer, surging demand for new gene therapy, and preclinical studies for cancer immunotherapy. According to the American Society of Gene Cell Therapy, around 97% of CAR T-cell therapies are developed for cancer indications
• The CNS conditions segment is anticipated to register the fastest growth, owing to the effectiveness of different model-based investigational compounds targeting brain diseases is expected to drive segment growth
• The GLP toxicology segment accounted for the largest market share in 2023 owing to the increasing number of standardized studies conducted according to specific guidelines
• North America held the largest revenue share of 50.0% in in-vivo CRO market in 2023. The growth in the region can be attributed to the presence of well-established market players, the increasing burden of different diseases, growing demand for CROs in the region. Other factors contributing to the growth are increased research and development activities, preclinical studies, and innovations of market players.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Model Type
  • 1.2.2. Modality
  • 1.2.3. Indication
  • 1.2.4. GLP Type
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Model type outlook
  • 2.2.2. Modality outlook
  • 2.2.3. Indication outlook
  • 2.2.4. GLP type outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. In Vivo CRO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Changing regulatory landscape
    • 3.2.1.2. Increase in offshoring medical device manufacturing to emerging countries
    • 3.2.1.3. Rising demand for advanced products
    • 3.2.1.4. Implementation of international standards by contract manufacturers
    • 3.2.1.5. Rising price competition and requirement to reduce cost
    • 3.2.1.6. Increasing complexity concerning product design and engineering
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Compliance issues while outsourcing
    • 3.2.2.2. Changing scenarios in developing countries
    • 3.2.2.3. Regulatory and legal compliance
    • 3.2.2.4. Contractual obligation
• 3.3. In Vivo CRO Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis

Chapter 4. In Vivo CRO Market: Model Type Estimates & Trend Analysis

• 4.1. Model Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global In Vivo CRO Market by Model Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Rodent based
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Rat models
    • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Mice models
    • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Others
    • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Non-rodent based
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. In Vivo CRO Market: Modality Estimates & Trend Analysis

• 5.1. Modality Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global In Vivo CRO Market by Modality Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Small molecules
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Large molecules
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2. Cell & gene therapy
    • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2.2. CAR T-cell therapies
    • 5.4.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2.3. CAR-NK cell therapies
    • 5.4.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2.4. TCR-T cell therapies
    • 5.4.2.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2.5. Other (Includes- TCR-NK, CARM, and TAC-T)
    • 5.4.2.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. RNA therapy
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. In Vivo CRO Market: Indication Estimates & Trend Analysis

• 6.1. Indication Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global In Vivo CRO Market by Indication Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Oncology
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.2. Blood cancer
    • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3. Solid tumor
    • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3.2. Solid tumor
    • 6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3.2.2. Syngeneic model
    • 6.4.1.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3.2.3. Patient derived xenograft
    • 6.4.1.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3.2.4. Xenograft
    • 6.4.1.3.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3.3. Others
    • 6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. CNS conditions
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.2. Epilepsy
    • 6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.3. Parkinson's disease
    • 6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.4. Huntington's disease
    • 6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.5. Stroke
    • 6.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.6. Muscular dystrophy
    • 6.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.7. Alzheimer's disease
    • 6.4.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.8. Traumatic brain injury
    • 6.4.2.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.9. Amyotrophic lateral sclerosis (ALS)
    • 6.4.2.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.10. Spinal muscular atrophy
    • 6.4.2.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.11. Muscle regeneration
    • 6.4.2.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2.12. Other neurodevelopment disorders
    • 6.4.2.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Diabetes
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Obesity
    • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Pain management
    • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5.2. Chronic pain
    • 6.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5.3. Chronic pain
    • 6.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Autoimmune/inflammation conditions
    • 6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6.2. Rheumatoid arthritis
    • 6.4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6.3. Multiple sclerosis
    • 6.4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6.4. Osteoarthritis
    • 6.4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6.5. Irritable bowel syndrome
    • 6.4.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6.6. Others
    • 6.4.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Others
    • 6.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. In Vivo CRO Market: GLP Type Estimates & Trend Analysis

• 7.1. GLP Type Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global In Vivo CRO Market by GLP Type Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. GLP toxicology
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Non GLP
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. In Vivo CRO Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ reimbursement structure
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/ reimbursement structure
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. Mexico
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/ reimbursement structure
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework/ reimbursement structure
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ reimbursement structure
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ reimbursement structure
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ reimbursement structure
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2023
  • 9.3.4. IQVIA Inc.
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Crown Bioscience
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Taconic Biosciences, Inc.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. PsychoGenics Inc.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Evotec
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Janvier Labs
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Biocytogen Boston Corp
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. GemPharmatech
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Charles River Laboratories
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Icon Plc
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Labcorp Drug Development
    • 9.3.14.1. Company overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Product benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. Parexel International Corporation
    • 9.3.15.1. Company overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Product benchmarking
    • 9.3.15.4. Strategic initiatives
  • 9.3.16. SMO Clinical Research (I) Pvt Ltd.
    • 9.3.16.1. Company overview
    • 9.3.16.2. Financial performance
    • 9.3.16.3. Product benchmarking
    • 9.3.16.4. Strategic initiatives